SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001839882-21-002168
Filing Date
2021-02-16
Accepted
2021-02-16 17:27:30
Documents
1
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES X, L.P.ATLAS VENTURE ASSOCIATES X, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP kymr-sc13g_123120.htm SC 13G 171844
  Complete submission text file 0001839882-21-002168.txt   173667
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

IRS No.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139 857-285-5314
Kymera Therapeutics, Inc. (Subject) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91636 | Film No.: 21641077
SIC: 2836 Biological Products, (No Diagnostic Substances)